KDJ24003
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
PF-04950615,RN-316, CAS: 1407495-02-6
PCSK9 Inhibitors: The Evolving Future., PMID:39479289
PCSK9 Monoclonal Antibodies Have Come a Long Way., PMID:39384735
PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis., PMID:39040999
Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition-Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition., PMID:38924090
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies., PMID:38845069
Population PK/PD modeling of low-density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti-PCSK9 monoclonal antibody., PMID:37994400
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion., PMID:37682072
Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study., PMID:37658997
Selection of biophysically favorable antibody variants using a modified Flp-In CHO mammalian display platform., PMID:37229492
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials., PMID:37099141
Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review., PMID:36935878
Reduction of therapeutic antibody self-association using yeast-display selections and machine learning., PMID:36433737
Safety of PCSK9 inhibitors., PMID:36411665
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab., PMID:35708715
Regulatory Experience Assessing the Carcinogenic Potential of a Monoclonal Antibody Inhibiting PCSK9, Bococizumab, Including a 2-Year Carcinogenicity Study in Rats., PMID:35672934
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial., PMID:35378068
Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1., PMID:35277540
A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia., PMID:34754882
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials., PMID:34581425
Comparability study of monocyte derived dendritic cells, primary monocytes, and THP1 cells for innate immune responses., PMID:34508774
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression., PMID:33892045
Pleiotropic Effects of PCSK-9 Inhibitors., PMID:33808697
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials., PMID:33520801
The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials., PMID:33417682
Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?, PMID:33372537
Epitope characterization of anti-drug antibodies-a tool for discovery and health: an overview of the necessity of early epitope characterization to avoid anti-drug antibodies and promote patient health., PMID:33317351
Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries., PMID:33103593
PCSK9 Monoclonal Antibodies: An Overview., PMID:33014302
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update., PMID:32939318
Fit-for-Purpose Validation and Establishment of Assay Acceptance and Reporting Criteria of Dendritic Cell Activation Assay Contributing to the Assessment of Immunogenicity Risk., PMID:32839919
Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis., PMID:31910414
Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials., PMID:31823301
Efficacy and safety of PCSK9 monoclonal antibodies., PMID:31623472
PCSK9 inhibitors and cardiovascular outcomes., PMID:31593483
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects ., PMID:31549625
Discontinued Drugs for the Treatment of Cardiovascular Disease from 2016 to 2018., PMID:31547243
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies., PMID:31529318
PCSK9 inhibition and inflammation: A narrative review., PMID:31404822
Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins - Confirmation from PCSK9 Inhibitor Studies., PMID:31301293
Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials., PMID:30895178
Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials., PMID:30762200
[Comments on the most important and recent studies involving PCSK9i]., PMID:30704247
Pharmacokinetics, pharmacodynamics, and safety of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, in healthy subjects when administered in co-mixture with recombinant human hyaluronidase: A phase 1 randomized trial., PMID:30623096
Plasma proprotein convertase subtilisin/kexin type 9 inhibitors and cataract risk: A systematic review and meta-analysis., PMID:30502968
Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives., PMID:30317986
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease., PMID:30112987
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials., PMID:29949039
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy., PMID:29716940
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices., PMID:29688615
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab., PMID:29685591
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
